Teva Branded Pharm Drug Patent Portfolio
Teva Branded Pharm owns 16 orange book drugs protected by 95 US patents with Loestrin 24 Fe having the least patent protection, holding only 1 patent. And Austedo with maximum patent protection, holding 28 patents. Given below is the list of Teva Branded Pharm's drug patents along with their expiration dates.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US11266796 | Inhalation device with integrated electronics | 22 Feb, 2041 | Active |
US11173259 | Drug delivery device with electronics and power management | 06 Jul, 2040 | Active |
US11464923 | Inhaler system | 19 Jun, 2040 | Active |
US11439777 | Drug delivery device with electronics | 24 May, 2040 | Active |
US11344685 | Drug delivery device with electronics | 26 Sep, 2039 | Active |
US11000653 | Inhaler | 18 Dec, 2038 | Active |
US11357935 | Drug delivery device with electronics | 24 Sep, 2038 | Active |
US11179386 | Analogs of deutetrabenazine, their preparation and use | 15 Sep, 2038 | Active |
US11813232 | Analogs of deutetrabenazine, their preparation and use | 15 Sep, 2038 | Active |
US11179386 | Analogs of deutetrabenazine, their preparation and use | 15 Mar, 2038 | Active |
US11813232 | Analogs of deutetrabenazine, their preparation and use | 15 Mar, 2038 | Active |
US11351317 | Drug delivery device with electronics | 10 Feb, 2038 | Active |
US10959996 | Methods for the treatment of abnormal involuntary movement disorders | 07 Sep, 2036 | Active |
US11357772 | Methods for the treatment of abnormal involuntary movement disorders | 07 Sep, 2036 | Active |
US11446291 | Methods for the treatment of abnormal involuntary movement disorders | 07 Sep, 2036 | Active |
US11564917 | Methods for the treatment of abnormal involuntary movement disorders | 07 Sep, 2036 | Active |
US11648244 | Methods for the treatment of abnormal involuntary movement disorders | 07 Sep, 2036 | Active |
US12016858 | Methods for the treatment of abnormal involuntary movement disorders | 07 Sep, 2036 | Active |
US10569034 | Compliance monitoring module for a breath-actuated inhaler | 16 Aug, 2036 | Active |
US10959996 | Methods for the treatment of abnormal involuntary movement disorders | 07 Mar, 2036 | Active |
US11357772 | Methods for the treatment of abnormal involuntary movement disorders | 07 Mar, 2036 | Active |
US11446291 | Methods for the treatment of abnormal involuntary movement disorders | 07 Mar, 2036 | Active |
US11564917 | Methods for the treatment of abnormal involuntary movement disorders | 07 Mar, 2036 | Active |
US11648244 | Methods for the treatment of abnormal involuntary movement disorders | 07 Mar, 2036 | Active |
US12016858 | Methods for the treatment of abnormal involuntary movement disorders | 07 Mar, 2036 | Active |
US10918816 | Compliance monitoring module for a breath-actuated inhaler | 14 Dec, 2035 | Active |
US9782550 | Compliance monitoring module for a breath-actuated inhaler | 28 Aug, 2035 | Active |
US9782551 | Compliance monitoring module for a breath-actuated inhaler | 28 Aug, 2035 | Active |
US11666566 | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 | 18 Mar, 2034 | Active |
US9233959 | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 | 18 Mar, 2034 | Active |
US9296739 | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 | 18 Mar, 2034 | Active |
US9550780 | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 | 18 Mar, 2034 | Active |
US9814708 | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 | 18 Mar, 2034 | Active |
US11666566 | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 | 18 Sep, 2033 | Active |
US9233959 | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 | 18 Sep, 2033 | Active |
US9296739 | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 | 18 Sep, 2033 | Active |
US9550780 | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 | 18 Sep, 2033 | Active |
US9814708 | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 | 18 Sep, 2033 | Active |
US9327114 | User-activated self-contained co-packaged iontophoretic drug delivery system | 08 Oct, 2032 | Active |
US8978966 | Dose counters for inhalers, inhalers and methods of assembly thereof | 13 Jan, 2032 | Active |
US10561808 | Dose counter for inhaler having an anti-reverse rotation actuator | 01 Jan, 2032 | Active |
US10188811 | Nasal spray device | 21 Oct, 2031 | Active |
US8524733 | Benzoquinoline inhibitors of vesicular monoamine transporter 2 | 03 Oct, 2031 | Active |
US9216260 | Dose counters for inhalers, inhalers and methods of assembly thereof | 28 Jun, 2031 | Active |
US10022510 | Dose counters for inhalers, inhalers and methods of assembly thereof | 18 May, 2031 | Active |
US10124131 | Dose counter for inhaler having an anti-reverse rotation actuator | 18 May, 2031 | Active |
US9731087 | Dose counter for inhaler having a bore and shaft arrangement | 18 May, 2031 | Active |
US10022509 | Dose counter for inhaler having a bore and shaft arrangement | 18 May, 2031 | Active |
US10086156 | Dose counter for inhaler and method for counting doses | 18 May, 2031 | Active |
US10695512 | Dose counter for inhaler having an anti-reverse rotation actuator | 18 May, 2031 | Active |
US11395889 | Dose counter for inhaler having an anti-reverse rotation actuator | 18 May, 2031 | Active |
US9463289 | Dose counters for inhalers, inhalers and methods of assembly thereof | 18 May, 2031 | Active |
US9808587 | Dose counter for inhaler having an anti-reverse rotation actuator | 18 May, 2031 | Active |
US8524733 | Benzoquinoline inhibitors of vesicular monoamine transporter 2 | 03 Apr, 2031 | Active |
US8983594 | Electronic control of drug delivery system | 19 Nov, 2030 | Active |
US8445018 | Abuse resistant drug formulation | 31 Jul, 2029 | Active |
US8366600 | Polyamine enhanced formulations for triptan compound iontophoresis | 21 Apr, 2029 | Active |
US8415332 | Methods of hormonal treatment utilizing ascending-dose extended cycle regimens | 11 Mar, 2029 | Active |
US7855190 | Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration | 05 Dec, 2028 | Active |
US8132712 | Metered-dose inhaler | 07 Sep, 2028 | Active |
US8651103 | Dry powder inhalation apparatus | 26 Mar, 2028 | Active |
US9216176 | Abuse resistant drug formulation | 13 Sep, 2027 | Active |
US9572803 | Abuse resistant drug formulation | 13 Sep, 2027 | Active |
US9272137 | Transdermal methods and systems for the delivery of anti-migraine compounds | 07 Sep, 2027 | Active |
US7973058 | Transdermal methods and systems for the delivery of anti-migraine compounds | 12 Apr, 2027 | Active |
US8155737 | Pharmacokinetics of iontophoretic sumatriptan administration | 12 Apr, 2027 | Active |
US8470853 | Transdermal methods and systems for the delivery of anti-migraine compounds | 12 Apr, 2027 | Active |
US8597272 | Pharmacokinetics of iontophoretic sumatriptan administration | 12 Apr, 2027 | Active |
US9427578 | Pharmacokinetics of iontophoretic sumatriptan administration | 12 Apr, 2027 | Active |
US7780038 | Dispensing apparatus with dosage counter | 24 Jan, 2027 | Active |
US8450299 | Methods of hormonal treatment utilizing ascending-dose extended cycle regimens | 07 Oct, 2025 | Active |
US10765820 | Dry powder inhalation apparatus | 19 May, 2025 | Active |
US9463288 | Dry powder inhalation apparatus | 19 May, 2025 | Active |
US7320969 | Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology | 30 Jan, 2024 | Expired |
US7105152 | Suspension aerosol formulations | 12 Sep, 2023 | Expired |
US7858605 | Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology | 23 Jun, 2023 | Expired |
US7615545 | Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology | 15 Jun, 2023 | Expired |
US7540282 | Reservoir pressure system for medicament inhaler | 06 May, 2023 | Expired |
US6745071 | Iontophoretic drug delivery system | 21 Feb, 2023 | Expired |
US6701917 | Dose counter for medicament inhaler | 23 Jun, 2021 | Expired |
US6718972 | Dose metering system for medicament inhaler | 23 Jun, 2021 | Expired |
US6748947 | De-agglomerator for breath-actuated dry powder inhaler | 23 Jun, 2021 | Expired |
US6871646 | De-agglomerator for breath-actuated dry powder inhaler | 23 Jun, 2021 | Expired |
US8006690 | Reservoir pressure system for medicament inhaler | 23 Jun, 2021 | Expired |
US6156742 | Emergency contraceptive kit | 05 Dec, 2020 | Expired |
US6667050 | Chewable oral contraceptive | 06 Apr, 2019 | Expired |
US6446627 | Inhaler dose counter | 18 Dec, 2017 | Expired |
US5898032 | Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy | 23 Jun, 2017 | Expired |
USRE39861 | Methods of extended use oral contraception | 23 Jun, 2017 | Expired |
US7566445 | Medicinal aerosols and methods of delivery thereof | 04 Jun, 2017 | Expired |
US8834849 | Medicinal aerosols and methods of delivery thereof | 04 Jun, 2017 | Expired |
US5776432 | Beclomethasone solution aerosol formulations | 07 Jul, 2015 | Expired |
US5683677 | Medicinal aerosol formulations | 04 Nov, 2014 | Expired |
US5552394 | Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy | 22 Jul, 2014 | Expired |
US5605674 | Medicinal aerosol formulations | 25 Feb, 2014 | Expired |
Latest Legal Activities on Teva Branded Pharm's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Teva Branded Pharm.
Activity | Date | Patent Number |
---|---|---|
Payment of Maintenance Fee, 8th Year, Large Entity | 20 Jun, 2024 | US9550780 |
Expire Patent
Critical
| 10 Jun, 2024 | US9327114 |
Payment of Maintenance Fee, 8th Year, Large Entity | 21 Mar, 2024 | US9463288 |
Payment of Maintenance Fee, 8th Year, Large Entity | 21 Mar, 2024 | US9463288 |
Payment of Maintenance Fee, 8th Year, Large Entity | 21 Mar, 2024 | US9463289 |
Payment of Maintenance Fee, 4th Year, Large Entity | 21 Feb, 2024 | US10765820 |
Payment of Maintenance Fee, 4th Year, Large Entity | 21 Feb, 2024 | US10765820 |
Expire Patent
Critical
| 29 Jan, 2024 | US9216176 |
Maintenance Fee Reminder Mailed
Critical
| 25 Dec, 2023 | US9327114 |
Payment of Maintenance Fee, 4th Year, Large Entity | 22 Nov, 2023 | US10695512 |
Mail Patent eGrant Notification | 14 Nov, 2023 | US11813232 |
Recordation of Patent eGrant | 14 Nov, 2023 | US11813232 |
Patent eGrant Notification | 14 Nov, 2023 | US11813232 |
Email Notification
Critical
| 14 Nov, 2023 | US11813232 |
Patent Issue Date Used in PTA Calculation
Critical
| 14 Nov, 2023 | US11813232 |
Teva Branded Pharm's Drug Patent Litigations
Teva Branded Pharm's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Oct 26, 2018, against patent number US10561808. The petitioner , challenged the validity of this patent, with Declan Walsh et al. as the respondent. Click below to track the latest information on how companies are challenging Teva Branded Pharm's patents.
Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
---|---|---|---|---|
US8524733 | September, 2021 |
Terminated-Denied
(09 Mar, 2022)
| Auspex Pharmaceuticals, Inc. | Apotex Inc. |
US10561808 | October, 2018 |
Decision
(20 Sep, 2019)
| Declan Walsh et al. |
Teva Branded Pharm Drug Patents' Oppositions Filed in EPO
Teva Branded Pharm drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Sep 03, 2009, by Vectura Delivery Devices Limited. This opposition was filed on patent number EP01948660A. Click below to reveal the latest opposition data.
Application | Filing Date | Opposition Party | Legal Status |
---|---|---|---|
EP20172454A | Nov, 2022 | Vectura Limited | Granted and Under Opposition |
EP19155324A | Jun, 2021 | Vectura Limited | Granted and Under Opposition |
EP17811276A | Mar, 2021 | VECTURA DELIVERY DEVICES LIMITED | Opposition rejected |
EP17800844A | Jun, 2020 | Vectura Limited | Opposition rejected |
EP17800844A | Feb, 2020 | CHIESI FARMACEUTICI S.p.A. | Opposition rejected |
EP11779089A | Jan, 2016 | FRKelly | Opposition rejected |
EP01948660A | Aug, 2014 | Hexal Aktiengesellschaft | Patent maintained as amended |
EP02782404A | Jun, 2014 | Laboratorios Léon Farma, S.A. | Revoked |
EP02782404A | Jun, 2014 | Bröcher, Dirk Joachim | Revoked |
EP01948660A | Sep, 2009 | Vectura Delivery Devices Limited | Patent maintained as amended |
Teva Branded Pharm's Family Patents
Teva Branded Pharm Drug List
Given below is the complete list of Teva Branded Pharm's drugs and the patents protecting them.
1. Austedo
Austedo is protected by 28 patents, out of which none have expired yet. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US11179386
(Pediatric)
| Analogs of deutetrabenazine, their preparation and use |
15 Sep, 2038
(13 years from now)
| Active |
US11813232
(Pediatric)
| Analogs of deutetrabenazine, their preparation and use |
15 Sep, 2038
(13 years from now)
| Active |
US11179386 | Analogs of deutetrabenazine, their preparation and use |
15 Mar, 2038
(13 years from now)
| Active |
US11813232 | Analogs of deutetrabenazine, their preparation and use |
15 Mar, 2038
(13 years from now)
| Active |
US10959996
(Pediatric)
| Methods for the treatment of abnormal involuntary movement disorders |
07 Sep, 2036
(11 years from now)
| Active |
US11357772
(Pediatric)
| Methods for the treatment of abnormal involuntary movement disorders |
07 Sep, 2036
(11 years from now)
| Active |
US11446291
(Pediatric)
| Methods for the treatment of abnormal involuntary movement disorders |
07 Sep, 2036
(11 years from now)
| Active |
US11564917
(Pediatric)
| Methods for the treatment of abnormal involuntary movement disorders |
07 Sep, 2036
(11 years from now)
| Active |
US11648244
(Pediatric)
| Methods for the treatment of abnormal involuntary movement disorders |
07 Sep, 2036
(11 years from now)
| Active |
US12016858
(Pediatric)
| Methods for the treatment of abnormal involuntary movement disorders |
07 Sep, 2036
(11 years from now)
| Active |
US10959996 | Methods for the treatment of abnormal involuntary movement disorders |
07 Mar, 2036
(11 years from now)
| Active |
US11357772 | Methods for the treatment of abnormal involuntary movement disorders |
07 Mar, 2036
(11 years from now)
| Active |
US11446291 | Methods for the treatment of abnormal involuntary movement disorders |
07 Mar, 2036
(11 years from now)
| Active |
US11564917 | Methods for the treatment of abnormal involuntary movement disorders |
07 Mar, 2036
(11 years from now)
| Active |
US11648244 | Methods for the treatment of abnormal involuntary movement disorders |
07 Mar, 2036
(11 years from now)
| Active |
US12016858 | Methods for the treatment of abnormal involuntary movement disorders |
07 Mar, 2036
(11 years from now)
| Active |
US11666566
(Pediatric)
| Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
18 Mar, 2034
(9 years from now)
| Active |
US9233959
(Pediatric)
| Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
18 Mar, 2034
(9 years from now)
| Active |
US9296739
(Pediatric)
| Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
18 Mar, 2034
(9 years from now)
| Active |
US9550780
(Pediatric)
| Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
18 Mar, 2034
(9 years from now)
| Active |
US9814708
(Pediatric)
| Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
18 Mar, 2034
(9 years from now)
| Active |
US11666566 | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
18 Sep, 2033
(8 years from now)
| Active |
US9233959 | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
18 Sep, 2033
(8 years from now)
| Active |
US9296739 | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
18 Sep, 2033
(8 years from now)
| Active |
US9550780 | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
18 Sep, 2033
(8 years from now)
| Active |
US9814708 | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
18 Sep, 2033
(8 years from now)
| Active |
US8524733
(Pediatric)
| Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
03 Oct, 2031
(6 years from now)
| Active |
US8524733 | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
03 Apr, 2031
(6 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Austedo's drug page
2. Loestrin 24 Fe
Loestrin 24 Fe is protected by 1 patent, which has expired already. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US5552394 | Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy |
22 Jul, 2014
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Loestrin 24 Fe's drug page
3. Loseasonique
Loseasonique is protected by 3 patents, out of which 2 have expired. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US7855190 | Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration |
05 Dec, 2028
(4 years from now)
| Active |
US7858605 | Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology |
23 Jun, 2023
(1 year, 4 months ago)
| Expired |
US7615545 | Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology |
15 Jun, 2023
(1 year, 5 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Loseasonique's drug page
4. Norethindrone And Ethinyl Estradiol And Ferrous Fumarate
Norethindrone And Ethinyl Estradiol And Ferrous Fumarate is protected by 2 patents, out of which all have expired. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US6667050 | Chewable oral contraceptive |
06 Apr, 2019
(5 years ago)
| Expired |
US5552394 | Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy |
22 Jul, 2014
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Norethindrone And Ethinyl Estradiol And Ferrous Fumarate's drug page
5. Preven Emergency Contraceptive Kit
Preven Emergency Contraceptive Kit is protected by 1 patent, which has expired already. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US6156742 | Emergency contraceptive kit |
05 Dec, 2020
(3 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Preven Emergency Contraceptive Kit's drug page
Explore Our Curated Drug Screens
6. Proair Digihaler
Proair Digihaler is protected by 27 patents, out of which 6 have expired. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US11266796 | Inhalation device with integrated electronics |
22 Feb, 2041
(16 years from now)
| Active |
US11173259 | Drug delivery device with electronics and power management |
06 Jul, 2040
(15 years from now)
| Active |
US11464923 | Inhaler system |
19 Jun, 2040
(15 years from now)
| Active |
US11439777 | Drug delivery device with electronics |
24 May, 2040
(15 years from now)
| Active |
US11344685 | Drug delivery device with electronics |
26 Sep, 2039
(14 years from now)
| Active |
US11000653 | Inhaler |
18 Dec, 2038
(14 years from now)
| Active |
US11357935 | Drug delivery device with electronics |
24 Sep, 2038
(13 years from now)
| Active |
US11351317 | Drug delivery device with electronics |
10 Feb, 2038
(13 years from now)
| Active |
US10569034 | Compliance monitoring module for a breath-actuated inhaler |
16 Aug, 2036
(11 years from now)
| Active |
US10918816 | Compliance monitoring module for a breath-actuated inhaler |
14 Dec, 2035
(11 years from now)
| Active |
US9782550 | Compliance monitoring module for a breath-actuated inhaler |
28 Aug, 2035
(10 years from now)
| Active |
US9782551 | Compliance monitoring module for a breath-actuated inhaler |
28 Aug, 2035
(10 years from now)
| Active |
US8978966 | Dose counters for inhalers, inhalers and methods of assembly thereof |
13 Jan, 2032
(7 years from now)
| Active |
US10561808 | Dose counter for inhaler having an anti-reverse rotation actuator |
01 Jan, 2032
(7 years from now)
| Active |
US9216260 | Dose counters for inhalers, inhalers and methods of assembly thereof |
28 Jun, 2031
(6 years from now)
| Active |
US10022510 | Dose counters for inhalers, inhalers and methods of assembly thereof |
18 May, 2031
(6 years from now)
| Active |
US10124131 | Dose counter for inhaler having an anti-reverse rotation actuator |
18 May, 2031
(6 years from now)
| Active |
US9731087 | Dose counter for inhaler having a bore and shaft arrangement |
18 May, 2031
(6 years from now)
| Active |
US8651103 | Dry powder inhalation apparatus |
26 Mar, 2028
(3 years from now)
| Active |
US10765820 | Dry powder inhalation apparatus |
19 May, 2025
(5 months from now)
| Active |
US9463288 | Dry powder inhalation apparatus |
19 May, 2025
(5 months from now)
| Active |
US7540282 | Reservoir pressure system for medicament inhaler |
06 May, 2023
(1 year, 6 months ago)
| Expired |
US6701917 | Dose counter for medicament inhaler |
23 Jun, 2021
(3 years ago)
| Expired |
US6718972 | Dose metering system for medicament inhaler |
23 Jun, 2021
(3 years ago)
| Expired |
US6748947 | De-agglomerator for breath-actuated dry powder inhaler |
23 Jun, 2021
(3 years ago)
| Expired |
US6871646 | De-agglomerator for breath-actuated dry powder inhaler |
23 Jun, 2021
(3 years ago)
| Expired |
US8006690 | Reservoir pressure system for medicament inhaler |
23 Jun, 2021
(3 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Proair Digihaler's drug page
7. Proair Hfa
Proair Hfa is protected by 14 patents, out of which 5 have expired. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US10561808 | Dose counter for inhaler having an anti-reverse rotation actuator |
01 Jan, 2032
(7 years from now)
| Active |
US10022509 | Dose counter for inhaler having a bore and shaft arrangement |
18 May, 2031
(6 years from now)
| Active |
US10022510 | Dose counters for inhalers, inhalers and methods of assembly thereof |
18 May, 2031
(6 years from now)
| Active |
US10086156 | Dose counter for inhaler and method for counting doses |
18 May, 2031
(6 years from now)
| Active |
US10695512 | Dose counter for inhaler having an anti-reverse rotation actuator |
18 May, 2031
(6 years from now)
| Active |
US11395889 | Dose counter for inhaler having an anti-reverse rotation actuator |
18 May, 2031
(6 years from now)
| Active |
US9463289 | Dose counters for inhalers, inhalers and methods of assembly thereof |
18 May, 2031
(6 years from now)
| Active |
US9808587 | Dose counter for inhaler having an anti-reverse rotation actuator |
18 May, 2031
(6 years from now)
| Active |
US8132712 | Metered-dose inhaler |
07 Sep, 2028
(3 years from now)
| Active |
US7105152 | Suspension aerosol formulations |
12 Sep, 2023
(1 year, 2 months ago)
| Expired |
US6446627 | Inhaler dose counter |
18 Dec, 2017
(6 years ago)
| Expired |
US7566445 | Medicinal aerosols and methods of delivery thereof |
04 Jun, 2017
(7 years ago)
| Expired |
US8834849 | Medicinal aerosols and methods of delivery thereof |
04 Jun, 2017
(7 years ago)
| Expired |
US5605674 | Medicinal aerosol formulations |
25 Feb, 2014
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Proair Hfa's drug page
8. Proair Respiclick
Proair Respiclick is protected by 18 patents, out of which 7 have expired. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US9782550 | Compliance monitoring module for a breath-actuated inhaler |
28 Aug, 2035
(10 years from now)
| Active |
US9782551 | Compliance monitoring module for a breath-actuated inhaler |
28 Aug, 2035
(10 years from now)
| Active |
US8978966 | Dose counters for inhalers, inhalers and methods of assembly thereof |
13 Jan, 2032
(7 years from now)
| Active |
US10561808 | Dose counter for inhaler having an anti-reverse rotation actuator |
01 Jan, 2032
(7 years from now)
| Active |
US9216260 | Dose counters for inhalers, inhalers and methods of assembly thereof |
28 Jun, 2031
(6 years from now)
| Active |
US10022510 | Dose counters for inhalers, inhalers and methods of assembly thereof |
18 May, 2031
(6 years from now)
| Active |
US10124131 | Dose counter for inhaler having an anti-reverse rotation actuator |
18 May, 2031
(6 years from now)
| Active |
US9731087 | Dose counter for inhaler having a bore and shaft arrangement |
18 May, 2031
(6 years from now)
| Active |
US8651103 | Dry powder inhalation apparatus |
26 Mar, 2028
(3 years from now)
| Active |
US10765820 | Dry powder inhalation apparatus |
19 May, 2025
(5 months from now)
| Active |
US9463288 | Dry powder inhalation apparatus |
19 May, 2025
(5 months from now)
| Active |
US7540282 | Reservoir pressure system for medicament inhaler |
06 May, 2023
(1 year, 6 months ago)
| Expired |
US6701917 | Dose counter for medicament inhaler |
23 Jun, 2021
(3 years ago)
| Expired |
US6718972 | Dose metering system for medicament inhaler |
23 Jun, 2021
(3 years ago)
| Expired |
US6748947 | De-agglomerator for breath-actuated dry powder inhaler |
23 Jun, 2021
(3 years ago)
| Expired |
US6871646 | De-agglomerator for breath-actuated dry powder inhaler |
23 Jun, 2021
(3 years ago)
| Expired |
US8006690 | Reservoir pressure system for medicament inhaler |
23 Jun, 2021
(3 years ago)
| Expired |
US6446627 | Inhaler dose counter |
18 Dec, 2017
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Proair Respiclick's drug page
9. Qnasl
Qnasl is protected by 5 patents, out of which 3 have expired. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US10188811 | Nasal spray device |
21 Oct, 2031
(6 years from now)
| Active |
US7780038 | Dispensing apparatus with dosage counter |
24 Jan, 2027
(2 years from now)
| Active |
US5776432 | Beclomethasone solution aerosol formulations |
07 Jul, 2015
(9 years ago)
| Expired |
US5683677 | Medicinal aerosol formulations |
04 Nov, 2014
(10 years ago)
| Expired |
US5605674 | Medicinal aerosol formulations |
25 Feb, 2014
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Qnasl's drug page
10. Quartette
Quartette is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US8415332 | Methods of hormonal treatment utilizing ascending-dose extended cycle regimens |
11 Mar, 2029
(4 years from now)
| Active |
US8450299 | Methods of hormonal treatment utilizing ascending-dose extended cycle regimens |
07 Oct, 2025
(10 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Quartette's drug page
11. Qvar 40
Qvar 40 is protected by 12 patents, out of which 4 have expired. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US10561808 | Dose counter for inhaler having an anti-reverse rotation actuator |
01 Jan, 2032
(7 years from now)
| Active |
US10022509 | Dose counter for inhaler having a bore and shaft arrangement |
18 May, 2031
(6 years from now)
| Active |
US10022510 | Dose counters for inhalers, inhalers and methods of assembly thereof |
18 May, 2031
(6 years from now)
| Active |
US10086156 | Dose counter for inhaler and method for counting doses |
18 May, 2031
(6 years from now)
| Active |
US10695512 | Dose counter for inhaler having an anti-reverse rotation actuator |
18 May, 2031
(6 years from now)
| Active |
US11395889 | Dose counter for inhaler having an anti-reverse rotation actuator |
18 May, 2031
(6 years from now)
| Active |
US9463289 | Dose counters for inhalers, inhalers and methods of assembly thereof |
18 May, 2031
(6 years from now)
| Active |
US9808587 | Dose counter for inhaler having an anti-reverse rotation actuator |
18 May, 2031
(6 years from now)
| Active |
US6446627 | Inhaler dose counter |
18 Dec, 2017
(6 years ago)
| Expired |
US5776432 | Beclomethasone solution aerosol formulations |
07 Jul, 2015
(9 years ago)
| Expired |
US5683677 | Medicinal aerosol formulations |
04 Nov, 2014
(10 years ago)
| Expired |
US5605674 | Medicinal aerosol formulations |
25 Feb, 2014
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Qvar 40's drug page
12. Qvar 80
Qvar 80 is protected by 12 patents, out of which 4 have expired. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US10561808 | Dose counter for inhaler having an anti-reverse rotation actuator |
01 Jan, 2032
(7 years from now)
| Active |
US10022509 | Dose counter for inhaler having a bore and shaft arrangement |
18 May, 2031
(6 years from now)
| Active |
US10022510 | Dose counters for inhalers, inhalers and methods of assembly thereof |
18 May, 2031
(6 years from now)
| Active |
US10086156 | Dose counter for inhaler and method for counting doses |
18 May, 2031
(6 years from now)
| Active |
US10695512 | Dose counter for inhaler having an anti-reverse rotation actuator |
18 May, 2031
(6 years from now)
| Active |
US11395889 | Dose counter for inhaler having an anti-reverse rotation actuator |
18 May, 2031
(6 years from now)
| Active |
US9463289 | Dose counters for inhalers, inhalers and methods of assembly thereof |
18 May, 2031
(6 years from now)
| Active |
US9808587 | Dose counter for inhaler having an anti-reverse rotation actuator |
18 May, 2031
(6 years from now)
| Active |
US6446627 | Inhaler dose counter |
18 Dec, 2017
(6 years ago)
| Expired |
US5776432 | Beclomethasone solution aerosol formulations |
07 Jul, 2015
(9 years ago)
| Expired |
US5683677 | Medicinal aerosol formulations |
04 Nov, 2014
(10 years ago)
| Expired |
US5605674 | Medicinal aerosol formulations |
25 Feb, 2014
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Qvar 80's drug page
13. Seasonale
Seasonale is protected by 2 patents, out of which all have expired. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US5898032 | Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy |
23 Jun, 2017
(7 years ago)
| Expired |
USRE39861 | Methods of extended use oral contraception |
23 Jun, 2017
(7 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Seasonale's drug page
14. Seasonique
Seasonique is protected by 4 patents, out of which 3 have expired. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US7855190 | Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration |
05 Dec, 2028
(4 years from now)
| Active |
US7320969 | Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology |
30 Jan, 2024
(9 months ago)
| Expired |
US7858605 | Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology |
23 Jun, 2023
(1 year, 4 months ago)
| Expired |
US7615545 | Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology |
15 Jun, 2023
(1 year, 5 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Seasonique's drug page
15. Vantrela Er
Vantrela Er is protected by 3 patents, out of which none have expired yet. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US8445018 | Abuse resistant drug formulation |
31 Jul, 2029
(4 years from now)
| Active |
US9216176 | Abuse resistant drug formulation |
13 Sep, 2027
(2 years from now)
| Active |
US9572803 | Abuse resistant drug formulation |
13 Sep, 2027
(2 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vantrela Er's drug page
16. Zecuity
Zecuity is protected by 10 patents, out of which 1 has expired. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US9327114 | User-activated self-contained co-packaged iontophoretic drug delivery system |
08 Oct, 2032
(7 years from now)
| Active |
US8983594 | Electronic control of drug delivery system |
19 Nov, 2030
(5 years from now)
| Active |
US8366600 | Polyamine enhanced formulations for triptan compound iontophoresis |
21 Apr, 2029
(4 years from now)
| Active |
US9272137 | Transdermal methods and systems for the delivery of anti-migraine compounds |
07 Sep, 2027
(2 years from now)
| Active |
US7973058 | Transdermal methods and systems for the delivery of anti-migraine compounds |
12 Apr, 2027
(2 years from now)
| Active |
US8155737 | Pharmacokinetics of iontophoretic sumatriptan administration |
12 Apr, 2027
(2 years from now)
| Active |
US8470853 | Transdermal methods and systems for the delivery of anti-migraine compounds |
12 Apr, 2027
(2 years from now)
| Active |
US8597272 | Pharmacokinetics of iontophoretic sumatriptan administration |
12 Apr, 2027
(2 years from now)
| Active |
US9427578 | Pharmacokinetics of iontophoretic sumatriptan administration |
12 Apr, 2027
(2 years from now)
| Active |
US6745071 | Iontophoretic drug delivery system |
21 Feb, 2023
(1 year, 8 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zecuity's drug page